Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Status:
Completed

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.

Phase 3

Takeda